Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials

JAMA

Volumn 294, Issue 15, 2005, Pages 1934-1943

  Schneider, Lon S ^a,b   Dagerman, Karen S ^a   Insel, Philip ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DELUSION; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; HALLUCINATION; HUMAN; META ANALYSIS; MORTALITY; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 26844538114     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.15.1934     Document Type: Article

References (52)

1. 42 CFR §483.
2. Alexopoulos GS, Silver JM, Kahn DA, Frances A, Carpenter D. The Expert Consensus Guideline Series: Treatment of Agitation in Older Persons With Dementia. Minneapolis, Minn: McGraw-Hill Co; 1998:1-88.
3. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty J. The Expert Consensus Guideline Series: Treatment of Dementia and Its Behavioral Disturbances. Minneapolis, Minn: McGraw-Hill Co; 2005:1-111.
4. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial: Risperidone Study Group. J Clin Psychiatry. 1999;60:107-115.
5. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
6. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57:968-976.
7. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134-143.
8. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115-126.
9. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.
10. Chan W, Lam L, Choy C, Leung V, Li S, Chiu H. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16:1156-1162.
11. Tariot PN, Schneider LS, Katz IR, Mintzer JE, Street JS. Quetiapine in nursing home residents with Alzheimer's dementia and psychosis. Poster presented at: 15th Annual Meeting of the American Association for Geriatric Psychiatry; February 24-27, 2002; Orlando, Fla.
12. Tariot PN, Schneider LS, Katz IR, Mintzer JE, Street JS. Quetiapine in nursing home residents with Alzheimer's dementia and psychosis [abstract]. Am J Geriatr Psychiatry. 2002;10(2 suppl 1):93.
13. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? prospective study with necropsy follow up. BMJ. 1997;314:266-270.
14. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol. 1994;51:676-681.
15. Drevets W, Rubin E. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39-48.
16. Lopez O, Becker J, Brenner R, Rosen J, Bajaulaiye O, Reynolds C. Alzheimer's disease with delusions and hallucinations: neuropsychological and electrocephalographic correlates. Neurology. 1991;41:906-912.
17. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300-2307.
18. Stern Y, Mayeux R, Sano M, Hauser W, Bush T. Predictors of disease course in patients with probable Alzheimer's disease. Neurology. 1987;37:1649-1653.
19. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269-1270.
20. Medicines and Healthcare products Regulatory Agency. Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomised clinical trials of risperidone conducted in patients with dementia: March 9, 2004. Available at: http://medicines.mhra.gov.uk. Accessibility verified September 6, 2005.
21. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170:1395.
22. US Food and Drug Administration. Safety data on Zyprexa (olanzapine): hyperglycemia and diabetes. Available at: http://www.fda.gov/medwatch/SAFETY/ 2004/zyprexa.htm. Accessibility verified September 6, 2005.
23. Racoosin JA. Evaluating a safety signal in the postmarking period: cerebrovascular adverse events associated with risperidone and olanzapine. Paper presented at: 17th Annual Meeting of the American Association for Geriatric Psychiatry; February 21-24, 2004; Baltimore, Md.
24. Health Canada Therapeutic Products Directorate, Risperdal warning letter, October 11, 2002. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/2002/risperdal_hpc-cps_e.html. Accessibility verified September 20, 2005.
25. 21 CFR §312.32.
26. Mosholder A. FDA oral presentation. Paper presented at: 42nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting; June 10-13, 2002; Boca Raton, Fla.
27. US Food and Drug Administration. FDA Public Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 13, 2005.
28. Atypical antipsychotics in the elderly. Med Lett Drugs Ther. 2005;47:61-62.
29. The Cochrane Library, Issue 1, 2005. Chichester, England: John Wiley & Sons; 2005.
30. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29-34.
31. Schneider LS, Tariot PN, Mintzer J, Minkwitz M, Zhong K. Cerebrovascular adverse events and quetiapine: a pooled analysis in elderly patients with dementia. Paper presented at: 18th Annual Meeting of the American Association for Geriatric Psychiatry; March 3-6, 2005; San Diego, Calif.
32. Labeling Change for Abilify on Risk of CVA in Elderly. Bristol-Myers Squibb Medical Letter. February 10, 2005.
33. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330:874.
34. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analysis. BMJ. 2003;327:557-560.
35. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman D, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. London, England: BMJ Publication Group; 2001.
36. Howanitz E, Wisotzek I. Olanzapine versus placebo in the treatment of behavioral disturbances associated with vascular dementia. Presented at: 14th Annual Meeting of the American Association for Geriatric Psychiatry; February 23-26, 2001; San Francisco, Calif.
37. Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients [abstract]. Psychopharmacol Bull. 1995;31:534.
38. Breder C, Swanink R, Marcus R, et al. Dose-ranging study of aripiprazole in patients with Alzheimer's dementia. Presented at: 9th International Conference on Alzheimer's Disease and Related Disorders; July 17-22, 2004; Philadelphia, Pa.
39. Streim J, Breder C, Swanink R, McQuade R, Iwamoto T, Carson W. Flexible dose aripiprazole in psychosis of Alzheimer's dementia (AD). Poster presented at: 157th American Psychiatric Association Annual Meeting; May 1-6, 2004; New York, NY.
40. Kujawa M, Marcus R, Breder C, et al. Safety profile of aripiprazole in psychosis of Alzheimer's dementia: pooled analysis. Poster presented at: 9th International Conference on Alzheimer's Disease and Related Disorders; July 17-22, 2004; Philadelphia, Pa.
41. Stock E, Breder C, Goyvaerts H, et al. Safety profile of aripiprazole in psychosis of Alzheimer's dementia: pooled analysis. Poster presented at: American Psychiatric Association Annual Meeting; May 1-6, 2004; New York, NY.
42. De Deyn PP, Jeste DV, Mintzer JE, et al. Aripiprazole in dementia of the Alzheimer's type. Presented at: 16th Annual Meeting of the American Association for Geriatric Psychiatry; March 1-4, 2003; Honolulu, Hawaii.
43. Street JS, Tollefson GD, Tohen M, et al. Olanzapine for psychotic conditions in the elderly. Psychiatr Ann. 2000;30:191-196.
44. Street JS, Kinon B, Stauffer V. Olanzapine in dementia. In: Tran PV, ed. Olanzapine (Zyprexa): A Novel Antipsychotic. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:416-426.
45. Cavazzoni P, Young CA, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. Paper presented at: 44th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting (modifications added); June 1-4, 2004; Phoenix, Ariz.
46. Deberdt W, Dysken MW, Rappaport SA, et al. Placebo-controlled comparison of olanzapine and risperidone in the treatment of psychosis and behavioral disturbances in patients with dementia. Paper presented at: American Geriatrics Society; May 17-21, 2004; Las Vegas, Nev.
47. Kennedy JS, Young CA, Hoffman VP, Feldman PD, Deberdt W. A placebo-controlled 10-week prospective comparison of the occurrence of falls in dementia: olanzapine versus risperidone. Poster presented at: International College of Geriatric Psychoneuropharmacology; October 10-12, 2002; Barcelona, Spain.
48. Kennedy JS, Deberdt W, Micca J, et al. The effect of olanzapine on cognition in patients with Alzheimer's disease without psychosis or agitation. Poster presented at: International College of Geriatric Psychoneuropharmacology; October 14-16, 2004; Basel, Switzerland.
49. Zhong K, Tariot P, Minkwitz M, Devine N, Mintzer J. Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: a randomized, double-blind trial. Poster presented at: 9th International Conference on Alzheimer's Disease and Related Disorders; July 17-22, 2004; Philadelphia, Pa.
50. De Deyn PP, DeSmedt G. Risperidone in the treatment of behavioral disturbances in elderly patients with dementia. Presented at: Eighth Congress of the International Psychogeriatric Association; August 17-22, 1997; Jerusalem, Israel.
51. Mintzer J, Weiner M, Greenspan A, et al. Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer's disease. Poster presented at: International College of Geriatric Psychopharmacology; October 14-17, 2004; Basel, Switzerland.
52. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329:75.